Aerie Pharmaceuticals, which develops therapies for treating glaucoma and other eye diseases, has priced its IPO, saying this morning that it is offering up 6,720,000 share os its common stock at $10.00 per share. The company said it will begin trading on the NASDAQ Global Market this morning as AERI. Aerie had filed for an IPO last month. The company is venture backed by ACP, Clarus Lifesciences, Sofinnova Venture Partners, and TPG Biotech. The company's operations are split between Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach.
Top NewsFriday, October 25, 2013
Aerie Pharmaceuticals Prices IPO